WebDoctor Encyclopedia

Article

EGFR Inhibitors (EGFR Tyrosine Kinase Inhibitors)

What are EGFR inhibitors?

EGFR inhibitors are targeted cancer medicines that block the epidermal growth factor receptor (EGFR), a protein on the surface of cells that signals them to grow and divide. This article focuses on the EGFR tyrosine kinase inhibitors (TKIs), tablets that switch off the receptor from inside the cell. They are used mainly for non-small cell lung cancer (NSCLC) with an EGFR mutation.

In some lung cancers, the EGFR gene carries a mutation that leaves the receptor permanently switched on, driving uncontrolled growth. Tablets such as osimertinib, gefitinib, erlotinib, afatinib and dacomitinib fit into the receptor’s energy-binding pocket and block the signal. For people whose cancer carries one of these mutations, the response can be dramatic, with tumours shrinking within weeks.

EGFR mutations are found in about 10-15% of lung adenocarcinomas in Europe and North America, and in a much higher proportion in East Asia. They are more common in people who have never smoked, in women, and in adenocarcinoma, but anyone with NSCLC should be tested.

A different group of EGFR-blocking drugs, the antibodies cetuximab and panitumumab, works from outside the cell and is used in bowel and head and neck cancers. These are mentioned only briefly in this article.

A brief history

Gefitinib and erlotinib were developed in the late 1990s and early 2000s, but early trials in unselected lung cancer patients showed only modest overall benefit. In 2004, researchers discovered that the people who responded remarkably well had specific EGFR mutations. This finding transformed lung cancer care, establishing routine genetic testing. Later generations of TKIs, culminating in osimertinib, were designed to overcome resistance and to reach the brain more effectively.

1. Key facts at a glance

Feature Details
Type of treatment Targeted therapy (EGFR tyrosine kinase inhibitors)
Main use Non-small cell lung cancer with an EGFR mutation
How it is given Tablet taken once a day at home
Course length As long as it works for advanced cancer; 3 years after surgery
Test needed EGFR mutation testing on tumour tissue or blood
Common side effects Acne-like rash, diarrhoea, dry skin, nail infections, mouth sores
Less common risks Lung inflammation, heart effects (osimertinib)

2. How it works

The EGFR pathway

When growth signals bind EGFR, two receptors pair up and the kinase part inside the cell is switched on, using ATP to pass the signal down a chain of proteins. Mutated EGFR is active even without a growth signal. TKIs block the ATP pocket, so the signal stops and the cancer cells stop growing and die.

Common EGFR mutations

Mutation Frequency Sensitivity to TKIs
Exon 19 deletion About 45% of EGFR mutations Very sensitive
L858R (exon 21) About 40% Very sensitive
Uncommon mutations (G719X, L861Q, S768I) Small proportion Usually sensitive, especially to afatinib or osimertinib
Exon 20 insertions Small proportion Generally resistant to standard TKIs; other drugs used
T790M Usually develops on treatment Resistant to older TKIs; sensitive to osimertinib

Generations of EGFR TKIs

Generation Drugs Features
First Gefitinib, erlotinib Reversible binding
Second Afatinib, dacomitinib Irreversible binding; more side effects
Third Osimertinib Targets T790M; spares normal EGFR more; good brain penetration

EGFR TKIs belong to the wider family of kinase inhibitors, which also includes imatinib and related drugs and TRK inhibitors.

3. Who it is for

Conditions treated

Condition Role of EGFR TKIs
Non-small cell lung cancer First treatment for advanced EGFR-mutated disease; after surgery for stage IB-IIIA
Lung adenocarcinoma The subtype in which EGFR mutations are most common
Large cell lung carcinoma Rarely, if an EGFR mutation is found

Settings

Setting Use
Advanced or metastatic Osimertinib is the usual first choice, sometimes with chemotherapy or other drugs
After surgery Osimertinib for 3 years in stage IB-IIIA disease
After chemoradiotherapy Osimertinib in unresectable stage III disease

4. Before treatment

Step Why it is done
Biopsy Confirms NSCLC
Molecular testing Identifies EGFR and other driver mutations
Liquid biopsy Blood test for tumour DNA when tissue is limited
Staging scans CT, PET-CT and brain MRI
Heart tracing (ECG) and heart scan Osimertinib can affect heart rhythm and function
Blood tests Liver and kidney function
Medicines review Antacids and some other drugs affect absorption

Tissue or blood testing?

Testing tumour tissue remains the gold standard, because it can look for many genetic changes at once and confirm the cancer type. However, biopsies of lung tumours can be small or difficult to obtain. A liquid biopsy looks for fragments of tumour DNA in a blood sample. A positive blood result can be acted on straight away, but a negative result does not rule out a mutation, so tissue testing may still be needed.

Why not start straight away?

Waiting for test results, which can take one to three weeks, can feel frustrating when you want treatment to begin. However, starting chemotherapy or immunotherapy before the results are known may lead to the wrong treatment. If symptoms are severe, your team can discuss options while waiting.

5. What to expect: step by step

Step What happens
1. Starting tablets Once daily at home
2. Early review After 2-4 weeks to check side effects
3. Skin care Moisturisers and sunscreen from day one
4. Scans After about 2-3 months, then every few months
5. Ongoing treatment Continued as long as the cancer is controlled
6. Progression Biopsy or blood test to look for resistance mechanisms
7. Next treatment Chosen based on the resistance found

6. Side effects and risks

Side effect Notes
Acne-like rash Face, chest and back; very common with older TKIs, milder with osimertinib
Dry, itchy skin Regular moisturising helps
Diarrhoea Usually mild; loperamide helps
Nail fold infections (paronychia) Sore, swollen skin around nails
Mouth sores Mouthwashes and soft foods
Eye irritation Dry eyes, changes in eyelashes
Lung inflammation (interstitial lung disease) Rare but serious; report breathlessness or cough
Heart rhythm changes or reduced heart function Mainly osimertinib; monitored
Liver changes Monitored with blood tests

In the FLAURA trial, serious side effects were less common with osimertinib than with the older TKIs (34% vs 45%) (Soria et al., 2018).

Managing the rash

The rash often appears in the first few weeks. Doctors sometimes recommend antibiotics such as doxycycline to prevent or treat it, along with gentle cleansers, moisturisers and sun protection. A rash is often a sign that the drug is working, and it can usually be controlled without stopping treatment.

7. Results and outlook

Study Main finding
IPASS, East Asian patients with adenocarcinoma Gefitinib was much better than chemotherapy for people with EGFR mutations but worse for those without, establishing the need for testing (Mok et al., 2009)
FLAURA, untreated advanced EGFR-mutated NSCLC Osimertinib nearly doubled progression-free survival compared with older TKIs (18.9 vs 10.2 months) (Soria et al., 2018)
FLAURA overall survival Median survival was 38.6 months with osimertinib compared with 31.8 months with older TKIs (Ramalingam et al., 2020)
ADAURA, after surgery (682 people) At 2 years, 89% of people taking osimertinib were alive and disease-free compared with 52% taking placebo (Wu et al., 2020)

Why testing matters

The IPASS trial showed that the same drug could help or harm depending on the tumour’s genetics. In people without an EGFR mutation, progression-free survival was longer with chemotherapy than with gefitinib (Mok et al., 2009). This is why molecular testing before treatment is essential.

8. Recovery and aftercare

Living with daily tablets

Tip Why
Take the tablet at the same time each day Keeps steady levels
Moisturise skin twice daily Prevents dryness and cracking
Use high-factor sunscreen Skin is more sensitive to sun
Keep nails short and avoid biting them Reduces nail infections
Report breathlessness or cough promptly Possible lung inflammation
Check before taking indigestion remedies Some reduce absorption

When resistance develops

Almost all advanced EGFR-mutated cancers eventually become resistant. A new biopsy or blood test can show why. Possible causes include new EGFR mutations, activation of other pathways such as MET, or a change in the cancer’s appearance. In a small number of people, the cancer transforms into small cell lung cancer, which is then treated with chemotherapy such as etoposide-platinum.

Fertility and pregnancy

EGFR TKIs may harm a developing baby, so reliable contraception is needed during treatment and for a period afterwards. Because many people with EGFR-positive lung cancer are relatively young, discussing fertility and family planning early is important.

Interactions with other medicines

Some medicines and supplements change the level of EGFR TKIs in the blood. Strong acid-reducing drugs can reduce absorption of gefitinib and erlotinib, and St John’s wort can lower levels of several TKIs. Always check with your pharmacist before starting anything new, including herbal remedies.

Brain metastases

EGFR-mutated lung cancer often spreads to the brain. Osimertinib reaches the brain well, and in ADAURA, far fewer people taking it developed brain recurrence after surgery (Wu et al., 2020). Brain MRI scans are part of regular follow-up.

Coping with skin changes

Skin side effects can affect how people feel about their appearance, especially when the rash is on the face. Gentle, unperfumed skincare, light make-up designed for sensitive skin and early treatment of spots can help. Dermatology teams experienced with targeted drugs can offer further advice if the rash is troublesome.

Living well with EGFR-positive lung cancer

Many people take EGFR TKIs for years while working, travelling and enjoying family life. Patient groups specifically for EGFR-positive lung cancer offer peer support, information and advocacy. Maintaining physical activity and a healthy diet can help with energy and overall wellbeing.

EGFR antibodies in other cancers

The antibodies cetuximab and panitumumab also block EGFR, but from outside the cell. They are used in some bowel cancers without RAS mutations and in head and neck cancers, rather than for EGFR-mutated lung cancer. Their main side effect is a similar acne-like rash.

9. Alternatives

Alternative When it is considered
Chemotherapy After resistance, or combined with osimertinib in some people
Amivantamab-based treatment Exon 20 insertions, or after osimertinib
Immune checkpoint inhibitors Generally less effective in EGFR-mutated lung cancer
Radiotherapy Localised progression or symptom control
Surgery Early-stage disease
Clinical trials New drugs targeting resistance

10. Frequently asked questions

Question Answer
Is this chemotherapy? No, it is a targeted tablet
Will I lose my hair? Hair loss is uncommon, though hair may become thinner or curlier
Does a rash mean it is working? Often, but absence of rash does not mean the drug is not working
Can I drink alcohol? Moderate amounts are usually fine; check with your team
What if I miss a dose? Take it if within 12 hours; otherwise skip and continue as normal
Can I travel abroad? Usually yes; carry enough tablets and sunscreen
Did smoking cause my cancer? EGFR-mutated lung cancer often occurs in people who never smoked
Can I have radiotherapy at the same time? Often, for example to a painful bone, with careful planning
How long will I take the tablets? As long as they work, or 3 years after surgery

11. Questions to ask your care team

  • What EGFR mutation does my cancer have?
  • Which TKI do you recommend, and why?
  • Should I have chemotherapy alongside it?
  • How can I prevent and manage skin side effects?
  • How often will I have scans, including of the brain?
  • What happens when the drug stops working?
  • Are there clinical trials I could join?

Resources

  1. Mok, T.S. et al. (2009) ‘Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma’, New England Journal of Medicine, 361(10), pp. 947-957.
  2. Ramalingam, S.S. et al. (2020) ‘Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC’, New England Journal of Medicine, 382(1), pp. 41-50.
  3. Soria, J.C. et al. (2018) ‘Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer’, New England Journal of Medicine, 378(2), pp. 113-125.
  4. Wu, Y.L. et al. (2020) ‘Osimertinib in resected EGFR-mutated non-small-cell lung cancer’, New England Journal of Medicine, 383(18), pp. 1711-1723.
  5. National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).
  6. National Cancer Institute (2026) Osimertinib Mesylate. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib (Accessed: October 2026).

Prepared by the editorial team, October 2026.